



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



Comparative study between the effect of Single Anastomosis Gastric Bypass versus Roux-en-Y gastric Bypass in morbidly obese patient as regard remission of type-2 DM.

Thesis

*Submitted for partial fulfilment of Master degree in
General Surgery*

By

Nader Mohamed Abouzekry

M. B. B. Ch, - MS in General Surgery, Ain Shams University.

Under supervision of

Prof. DR. Mohamed Fayek Mohamed Mahfouz

Assistant Professor of General Surgery

Faculty of medicine-Ain Shams University.

Dr. Ayman Hossam Eldin Abdelmonaem

Lecturer of General Surgery

Faculty of Medicine-Ain Shams University.

Dr. Nahla Nader Adly

Lecturer of General Medicine and endocrinology

Faculty of Medicine-Ain Shams University.

Faculty of Medicine

Ain Shams University

2021

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**,
the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Khaled Gawdat**, Head of Surgery department and head of Bariatric Surgery Unit, Faculty of Medicine-Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Assist. Prof. Dr. Mohamed Fayek Mohamed Mahfouz**, Assistant Professor of General Surgery Faculty of Medicine-Ain Shams University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Ayman Hossam Eldin Abdelmonaem**, Lecturer of General Surgery Faculty of Medicine-Ain Shams University, for his great help, active participation and guidance.*

*I wish to introduce my deep respect and thanks to **Dr. Nahla Mader Adly**, Lecturer of Internal Medicine and*

*Endocrinology Faculty of Medicine-Ain Shams University, for
her kindness, supervision and cooperation in this work.*

Nader Abouzekry

List of Contents

Title	Page No.
List of Tables	i
List of Figures	ii
List of Abbreviations.....	iv
Introduction	i
Aim of the Work.....	4
Review of Literature	
Anatomy.....	5
Physiology of Digestive System.....	10
Pathology of Obesity	16
History & Types of Operations.....	35
DIAREM Scoring System	51
Indication, Contraindication and Complications of Bariatric Surgery.....	55
Methodology.....	66
Results	81
Discussion	95
Summary and Conclusion.....	101
References	103
Arabic Summary	—

List of Tables

Table No.	Title	Page No.
Table (1):	DiaRem scoring system and probability of remission	3
Table (2):	Adipocyte Secretagogues—Mechanism of Action	26
Table (3):	ABCD score.....	53
Table (4):	Summary of management protocols.....	65
Table (5):	Demographic data, preoperative HBA1C level and type of treatment of both study groups.....	82
Table (6):	Mean, SD and Range of Age, Height, Weight and BMI in each study group.	83
Table (7):	HBA1C and type of treatment in each study group.	86
Table (8):	Preoperative duration of DM.....	86
Table (9):	DiaRem score distribution among each study group.....	89
Table (10):	Percentage of remission “ recovery” in each study group.	90
Table (11):	Percentage of recovery in each DiaRem scoring strata in comparison to suspected value	91
Table (12):	Mean time of recovery of each group in each strata	93
Table (13):	Comparison between the resolution of DM for the present study and others after 1 year.....	98

List of Figures

Fig. No.	Title	Page No.
Figure (1):	The proximal gastric surgical unit.....	5
Figure (2):	Distal Gastric Surgical Unit.....	7
Figure (3):	The distal gastric surgical unit.....	9
Figure (4):	Role of lipotoxicity and inflammation on obesity	19
Figure (5):	Role of inflammation and immune dysfunction in obesity.....	23
Figure (6):	Jejuno-ileal bypass.....	36
Figure (7):	Gastric bypass as a bariatric surgery proposed by Mason & Ito.....	37
Figure (8):	Fobi-capella banded gastric bypass	38
Figure (9):	Roux en Y Gastric bypass.....	39
Figure (10):	One anastomosis Gastric bypass	40
Figure (11):	Vertical banded gastroplasty.....	42
Eh Figure (12):	 Adjustable Gastric band.	43
Figure (13):	Jujeno-ileal bypass.....	44
Figure (14):	Bilio-pancreatic diversion.....	45
Figure (15):	Single anastomosis duodeno-ileal bypass sleeve gastrectomy.....	47
Figure (16):	Magenstrasse & Mill operation.....	48
Figure (17):	Sleeve Gastrectomy	49

List of Figures Cont...

Fig. No.	Title	Page No.
Figure (18):	Roux en Y: creation of gastric pouch.	
Figure (19):	Roux-en-y: end-to-side anastomosis using 30mm linear stapler.	
Figure (20):	MGB/OAGB: Creation of the gastric pouch along Lesser curvature of the stomach.	77
Figure (21):	MGB/OAGB: Closure of the stapling defect of the gastrojejunostomy.	78
Figure (22):	Age in both group A & B.....	84
Figure (23):	Height in both group A & B.....	84
Figure (24):	Weight in both group A & B	85
Figure (25):	BMI in both group A & B	85
Figure (26):	HBA1C in both group A & B.....	87
Figure (27):	Type of treatment in each group.	87
Figure (28):	Distribution of treatment among both study groups.	88
Figure (29):	Distribution of patients over DiaRem scoring system strata	89
Figure (30);	Percentage of remission in each study group	92
Figure (31):	Average time of recovery	92
Figure (32):	Time till recovery in each strata in each group	93

List of Abbreviations

Abb.	Full term
AgRP.....	Agouti related protein
BMI.....	Body mass index
CCK.....	Cholecystokinin
CRP.....	C-Reactive protein
DiaRem.....	Diabetes Remission
ER.....	Endoplasmic reticulum
EWL.....	Excess weight loss
FFA.....	Free fatty acid
FGF.....	Fibroblastic growth factor
GEJ.....	Gastro-esophageal junction
GERD	Gastro-esophageal reflux disease
GIP.....	Gastric inhibitory peptide
HBA1C	Haemoglobin A1C
ICAM	Intercellular adhesive molecule
IFN	Interferon
IKKB.....	Inhibitor of NF-KB Kinase B
IL	Interleukin
IM	Intestinal metaplasia
IP10	Inducible protein 10
IRS.....	Insulin receptor substrate
JNK	Jun N-terminal kinase
LDL.....	Low density lipoprotein
LMGB/OAGBP ...	Laparoscopic mini gastric bypass
MAPK.....	Mitogen activated protein kinase
MCP-1.....	Monocyte chemoattractant protein 1
MMIF.....	Macrophage migration inhibiting factor
NAFLD	Non alcoholic fatty liver disease
NASH	Non alcoholic steatohepatitis
NF-KB	Nuclear factor kappa-beta
NS.....	Nervous system

List of Abbreviations Cont...

Abb.	Full term
OAGB	One anastomosis gastric bypass
OSA.....	Obstructive sleep apnea
PAI-1.....	Plasminogen activator inhibitor -1
RANTES.....	Regulate upon activation of novel T-cell expression sequences
RAS.....	Renin angiotensin system
RY-GBP	Roux en Y gastric bypass
SAA.....	Serum amyloid A
SMC	Smooth muscle cell
SOCS	Suppressor of cytokine signaling
T2DM.....	Type 2 Diabetes Mellitus
TG	Triglyceride
TGF.....	Tumor growth factor
TNF	Tumor necrotic factor
VCAM.....	Vascular cell adhesion molecule
VEGF.....	Vascular endothelial growth factor
VIP.....	Vasoactive intestinal peptide
WAT.....	White adipose tissue

INTRODUCTION

Obesity is a pandemic health problem in both developed and developing countries and the costs of care continue to grow in parallel with the prevalence of the disease. This morbid condition leads to a high incidence of complications and a decrease in life expectancy, especially among younger adults (*Fontaine et al., 2013*).

Surgical treatment of morbid obesity results in significant sustained weight loss, which reduces obesity-related morbidity and increases survival compared with patients receiving optimal medical therapy (*Sjostrom et al., 2007*).

Several conventional and novel methods of bariatric surgery—termed metabolic surgeries — induce long-term remission of type 2 diabetes mellitus (T2DM) and dramatically improve other metabolic abnormalities, such as hyperlipidemia and hypertension, independent of the patients' weight. Some previous studies demonstrated that these metabolic effects are not only attributable to drastic weight loss and diminished caloric intake, but also to endocrine changes that result from surgical manipulation of the gastrointestinal tract (*Rubino et al., 2010*).

Laparoscopic mini gastric bypass (LMGB/OAGBP), described by Rutledge, has a lower operative morbidity with equivalent efficacy compared to laparoscopic Roux-en-Y

gastric bypass (RY-GBP), in terms of resolution of the metabolic syndrome, loss of excess weight (EWL) and improvement of the quality of life (*Lee et al., 2005*).

Considering the escalating pandemic of T2DM, clinicians must recognize the need for improved therapeutic options. When behavioral and pharmacological interventions fail to manage T2DM, metabolic surgery offers an effective alternative, with the potential of complete remission of the disease (*Rubino et al., 2010*).

Whilst considered cost-effective and safe, the availability of the operation is unable to meet the demand due to the rapidly rising prevalence of obesity (*Warren et al., 2015*).

Furthermore, although metabolic surgery may result in improvement in obesity co-morbidities, not all patients with diabetes undergo remission. In the context of a health service with limited resources, a predictive score for the probability of significant diabetes improvement is required to target surgery only to those most likely to benefit. Current predictive scores include the DiaRem score (*Still et al., 2014*).

Various mechanisms have been proposed for predicting Type 2 DM remission. Durable Type 2 DM remission has been associated with early diabetes stage and significant percent excess body weight loss (%EWL). While, failure to achieve long-term remission has been associated with inadequate

weight loss beside use of insulin and high percent of glycated haemoglobin (*Still et al., 2014*).

The DiaRem score, which is based on a retrospective study of 690 patients with diabetes (most were followed up for ≤ 2 years), was created using a Cox regression model, and four preoperative clinical variables were identified in the final scoring model: insulin use, age, HbA1c, and type of antidiabetic drugs used. On the basis of the DiaRem score (ranging from 0 to 22), patients were classified into five groups (*Ali et al., 2014*).

Table (1): DiaRem scoring system and probability of remission (*Craig et al., 2018*).

Prediction factor		Score														
Age (years)	If age <40, enter 0 →	2														
	If age 40–49, enter 1 →															
	If age 50–59, enter 2 →															
	If age 60+, enter 3 →															
HbA1c (%)	If HbA1c <6.5, enter 0 →	4														
	If HbA1c 6.5–6.9, enter 2 →															
	If HbA1c 7.0–8.9, enter 4 →															
	If HbA1c >9, enter 6 →															
Diabetes medication	If not sulfonylureas or ISA*, enter 0 →	3														
	If sulfonylureas or ISA*, enter 3 →															
Insulin treatment	If not on insulin, enter 0 →	10														
	If on insulin, enter 10 →															
DiaRem score (sum) →		19														
				<table><tr><th>DiaRem score</th><th>Probability of remission</th></tr><tr><td>0–2</td><td>88%–99%</td></tr><tr><td>3–7</td><td>64%–88%</td></tr><tr><td>8–12</td><td>23%–49%</td></tr><tr><td>13–17</td><td>11%–33%</td></tr><tr><td>18–22</td><td>2%–16%</td></tr></table>	DiaRem score	Probability of remission	0–2	88%–99%	3–7	64%–88%	8–12	23%–49%	13–17	11%–33%	18–22	2%–16%
DiaRem score	Probability of remission															
0–2	88%–99%															
3–7	64%–88%															
8–12	23%–49%															
13–17	11%–33%															
18–22	2%–16%															

*Insulin sensitizing agent other than metformin